Chai Discovery Announces $130 Million Series B To Transform Molecular Discovery

Chai Discovery 宣布获得 1.3 亿美元 B 轮融资，推动分子发现变革

SAN FRANCISCO, December 15, 2025-- Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules, today announced its $130 million Series B financing round co-led by Oak HC/FT and General Catalyst. This round of financing values the company at $1.3 billion..

旧金山，2025年12月15日——Chai Discovery是一家预测并重新编程生化分子间相互作用的人工智能公司，今天宣布其由Oak HC/FT和General Catalyst共同领投的1.3亿美元B轮融资。此轮融资使公司估值达到13亿美元。

The news comes on the heels of Chai’s most recent announcement¹, where the company showed their latest models can now design molecules with important “developability” properties and tackle “hard-to-drug” targets that have historically been challenging for traditional techniques.

该消息紧随Chai最近的公告¹，该公司展示了其最新模型现在可以设计具有重要“可开发性”特性的分子，并解决传统技术历来难以应对的“难成药”靶点。

The round also comes just months after Chai Discovery announced a $70 million Series A and revealed Chai 2, the first zero-shot generative platform that achieves double digit experimental success rates in de novo antibody design – a 100-fold improvement over previous computational methods.

这一轮融资距离 Chai Discovery 宣布获得 7000 万美元的 A 轮融资并推出首个零样本生成平台 Chai 2 仅过去几个月。Chai 2 在从头抗体设计中实现了两位数的实验成功率，比之前的计算方法提高了 100 倍。

“We’re standing on the precipice of a new era for the biopharmaceutical industry,” said Josh Meier, co-founder and CEO of Chai Discovery. “We’re in awe of the rate of progress on the models – what looked like five-year problems just months ago are now getting solved in weeks. Our latest models can design molecules that have properties we’d want from actual drugs, and tackle challenging targets that have been out of reach.

“我们正站在生物制药行业新时代的边缘，”Chai Discovery的联合创始人兼首席执行官Josh Meier表示。“模型进展的速度让我们感到震撼——仅仅几个月前看似需要五年才能解决的问题，现在几周内就得到了解决。我们的最新模型可以设计出具备理想药物特性的分子，并应对以往难以触及的具有挑战性的靶点。”

These models will unleash a new wave of first-in-class and best-in-class therapeutics, and the early adopters in pharma will be the big winners.”.

这些模型将释放一波新的首创和同类最佳的治疗方法，而制药行业的早期采用者将成为最大的赢家。"

The fundraise was co-led by Oak HC/FT and General Catalyst, with participation from Thrive Capital, OpenAI, Dimension, Menlo Ventures, Lachy Groom, Yosemite, Neo, and SV Angel. New investors Emerson Collective and Glade Brook also joined the round.

本轮融资由橡树健康未来技术基金（Oak HC/FT）和通用催化剂（General Catalyst）共同领投，Thrive Capital、OpenAI、Dimension、门罗风投（Menlo Ventures）、拉奇·格鲁姆（Lachy Groom）、优胜美地（Yosemite）、新纪元（Neo）和SV Angel参与。新投资者艾默生集团（Emerson Collective）和格莱德布鲁克（Glade Brook）也加入了本轮融资。

“We believe biology is becoming programmable, rewiring what was once an empirical art into an engineered discipline,” said Elena Viboch, Managing Director at General Catalyst. “Chai’s team is leading this transformation – advancing the technical frontier and expanding what’s possible in therapeutics.”.

“我们认为生物学正在变得可编程，将曾经的经验艺术重新构建成一门工程学科，”General Catalyst董事总经理埃琳娜·维博奇表示。“Chai的团队正在引领这一变革——推进技术前沿并拓展治疗领域的可能性。”

By converting what has traditionally been a lengthy iteration cycle into a computational process, Chai can materially compress the time to first-in-human studies, tackle hard to drug and “undruggable” targets, and accelerate the overall time to commercialization.

通过将传统上漫长迭代周期转化为计算过程，Chai可以显著缩短首次人体研究的时间，攻克难以成药及“不可成药”靶点，并加速整体上市时间。

“Nowhere is AI transformation more needed than in drug development – the process is slow, expensive, and imprecise,” said Annie Lamont, Co-Founder & Managing Partner at Oak HC/FT. “It can take over a decade and cost upwards of a billion dollars to bring a medicine from bench to bedside. The Chai Discovery team is rewriting that story, fusing world-class AI and biological expertise to dramatically accelerate how medicines are discovered.

“人工智能转型在药物开发领域的需求尤为迫切——这一过程缓慢、昂贵且不精确，”Oak HC/FT联合创始人兼管理合伙人安妮·拉蒙特表示。“将一种药物从实验室带到临床可能需要十多年时间，并花费高达十亿美元。Chai Discovery团队正在改写这一故事，他们将世界级的人工智能与生物专业知识相结合，从而大幅加速药物的发现过程。”

We’re thrilled to support them as they push the boundaries of what’s possible in this field.”.

我们非常高兴支持他们突破这个领域的可能性界限。

The company will use the funding to accelerate research and product development, and expand commercialization efforts as they continue to execute on the vision of building a “computer-aided design suite” for molecules.

公司将利用这笔资金加速研究和产品开发，并在继续执行构建分子“计算机辅助设计套件”愿景的过程中，扩大商业化努力。

The Series B round brings Chai’s total funding to more than $225 million. As part of the fundraise, Annie Lamont from Oak HC/FT and Hemant Taneja from General Catalyst will be joining the board.

B轮融资使Chai的总融资额超过2.25亿美元。作为融资的一部分，Oak HC/FT的Annie Lamont和General Catalyst的Hemant Taneja将加入董事会。

For more information on Chai Discovery and its platform, visit https://www.chaidiscovery.com.

有关Chai Discovery及其平台的更多信息，请访问https://www.chaidiscovery.com。

About Chai Discovery

关于Chai Discovery

Chai Discovery builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, the fundamental building blocks of life. Its mission is to transform biology from science into engineering. The team hails from pioneering research and applied AI companies such as OpenAI, Meta FAIR, Stripe, and Google X, and is backed by top investors including OpenAI, Thrive Capital, Menlo Ventures, and Dimension..

Chai Discovery 致力于开发前沿人工智能，用于预测和重新编程生化分子之间的相互作用，这些分子是生命的基本组成部分。其使命是将生物学从科学转变为工程学。团队成员来自开创性研究机构和应用人工智能公司，如 OpenAI、Meta FAIR、Stripe 和 Google X，并受到包括 OpenAI、Thrive Capital、Menlo Ventures 和 Dimension 在内的顶级投资者支持。

About Oak HC/FT

关于Oak HC/FT

Oak HC/FT is a venture and growth equity firm specializing in investments in fintech and healthcare. Using partnership as a foundation, Oak HC/FT guides companies and founders at every stage, from seed to growth, to create businesses that make a measurable and lasting impact. Founded in 2014, Oak HC/FT has invested in more than 100 portfolio companies and has over $5.3 billion in assets under management.

Oak HC/FT 是一家专注于金融科技和医疗保健领域投资的风险和成长股权公司。Oak HC/FT 以合作为基础，指导处于各个阶段的公司和创始人，从种子期到成长期，致力于打造产生可衡量且持久影响的企业。自 2014 年成立以来，Oak HC/FT 已投资了 100 多家投资组合公司，管理资产超过 53 亿美元。

Oak HC/FT is headquartered in Stamford, CT, with an office in San Francisco, CA. Follow Oak HC/FT on LinkedIn and X and learn more at https://www.oakhcft.com/..

奥克HC/FT总部位于康涅狄格州斯坦福市，在加利福尼亚州旧金山设有办事处。关注奥克HC/FT的LinkedIn和X，更多信息请访问https://www.oakhcft.com/。

About General Catalyst

关于通用催化剂

General Catalyst is a global investment and transformation company that partners with the world’s most ambitious entrepreneurs to drive resilience and applied AI.

General Catalyst 是一家全球投资和转型公司，与世界上最有抱负的企业家合作，推动韧性和应用人工智能。

We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond.

我们支持那些具有长期视野并挑战现状的创始人，与他们从种子阶段到成长阶段及以后进行合作。

With offices in the U.S., Europe, and India, we have supported the growth of 800+ businesses, including Airbnb, Anduril, Anthropic, Applied Intuition, Commure, Glean, Gusto, Helsing, Hubspot, Kayak, Livongo, Mistral, Ramp, Samsara, Snap, Stripe, Sword, and Zepto.

我们在美国、欧洲和印度设有办事处，已经支持了800多家企业的成长，包括Airbnb、Anduril、Anthropic、Applied Intuition、Commure、Glean、Gusto、Helsing、Hubspot、Kayak、Livongo、Mistral、Ramp、Samsara、Snap、Stripe、Sword和Zepto。

For more: www.generalcatalyst.com, @generalcatalyst

欲了解更多信息，请访问：www.generalcatalyst.com，@generalcatalyst

¹ https://chaiassets.com/chai-2/paper/technical_report_challenging_targets.pdf

¹ https://chaiassets.com/chai-2/paper/technical_report_challenging_targets.pdf

Contact:

联系人：

press@chaidiscovery.com

press@chaidiscovery.com